Just took a gamble on these.The Company deals in the making and selling of biocides.It's looking to get into the treatment of MRSA among other things.It's awaiting regulatory approval for selling it's technology to the food & hygiene sector.
It has just started trading on the AIM.

Will all due respect, I think that you do not know exactly how Byotrols product works. As a cleaning product, its biggest advantage is that you do not need to clear wards to use and is safe to use near food and patients. Byotrol are selling this as an ingredient and thus using the marketing power of other companies to promote their product. They plan to capitalise mostly by royalties. As you mention the NHS, you may be aware that Byotrol have completed an extensive trial in an NHS hospital and by all accounts the results have been very promising. The results are due to be announced at a conference next month. Apart from MRSA, this product can also be used in food processing plants as evidenced by the Norweigian Fishing Industry patent and the announcement today of a tie up with a company in the USA that sells 14m chickens per week.

While your concerns regarding revenue are also my concerns, I think that this will come. The product is selling. Not sure what fair value is and this one has fallen back before but since then several important milestones have been passed. This could be a winner.

Afternoon all,

I agree that this looks promising given the pace of developments with new products and new markets opening up, but given that in the last financials, the company had managed less than 100k in sales, one has to ask how long it will be before they can achieve break-even.

At the end of March, they had about 1 million in the bank - and with six months of the year now gone, the most they can expect to have left is 500k, even if sales have jumped considerably in comparison with the last reporting period

At least the SP is strong enough to support a fundraising, or so it would appear.

Hangon, I'm not sure I agree with your argument about having to prove the market domestically before going abroad.

Clothing retailers are a wholly different ballgame from chemical suppliers - and M&S is a good example of a company that had its head in the sand for a long time when it came to discerning customer wants. There are however many clothing retailers who have successfully exported their business, such as Zara (Spanish) and H&M (Dutch). I don't know if you can find these chains in Britain (although dim memory suggests there's a new-ish H&M in Bournemouth), but they appear to enjoy considerable success here in Germany.

That's by-the-by. I think that the argument for Byotrol's products abroad will be that those that need it will buy it. If it is ahead of the rest in its (niche) markets and priced correctly then it will see success. Early indications seem to be that this has a fair chance of taking place.

My understanding of the MRSA problem in the NHS is that lousy (no pun intended!) hygiene due to cost-cutting has been the principal cause of the bug's proliferation (although if you really want to get technical then indiscriminate use of antibiotics is also due a large portion of the blame for the bacterium developing its resistance to methicillin). If surfaces are treated with Byotrol products such as paints, this deprives MRSA of places in which to grow and also helps to bridge the cleanliness gap by creating long-term protection in areas which would previously have had to be cleaned and disinfected regularly.

I haven't looked at HCEG in detail, but at first blush their Ebiox anti-bacterial product appears not to be as versatile or as advanced as that of BYOT, so will not be a direct competitor.

Hope this helps; all IMO, etc.

For those who may be interested, I sent a mail to Byotrol on Weds asking about whether Byotrol could be dangerous to humans if it got into food. Here's the response. It concentrates more on Byotrol's degradability in the environment, but may be of interest.



RE: Byotrol in food - response from Stephen Falder, Director

Dear (Soul Traders),

Thank you for your question about Byotrol's technology and the microbial
ecosystem. I trust that I can reassure you with the following information
about how our technology controls microbes and to confirm to you that we
have spent significant resources during our research and development to
establish that Byotrol products generate no long term environmental
problems.

Byotrol formulations are not new chemicals but they are a patented way of
creating blends of biocides and preservatives with a polymer "backbone" that
significantly improves the performance against microbes, particularly
because they are effective even after they have dried onto surfaces. A
simple view is that the polymer backbone stays in place with the biocides in
our formulae "magnetically" stuck to the polymer (Hydrogen bonds or
similar). This is very stable and durable in clean water and materials like
soaps and similar and also when dried on a surface such as wood, steel,
glass or textiles,thus bringing huge advantages of lasting protection and
ease of use.

However the story rapidly changes in the environment and in particular in
waste water streams because the preservatives we use are not very stable on
their own in the environment (they get "eaten" by many species of microbe).
After approximately 24 hours in "dirty" water or similar compounds that are
natural and abundant in non-purified water, it starts to change the
structure, removing the biocide and associating with our backbone polymers
instead. This has the significant effect of releasing the biocide
components to be biodegraded. This happens after the products have been
finished with i.e. after their disposal and all of the biocides have been
tested extensively for quite rapid biodegradation. ( The ones we have chosen
are well understood and researched and already used in cosmetics, soaps,
etc.)

We therefore strongly believe that there is practically no possibility of
residue build up in the environment to create resistance or harmful mutated
strains. Additionally, the typical biocide we choose has a simple effect on
microbes lysing (bursting) the cell membranes, not interfering with the
reproductive biochemistry like an antibiotic or similar. A cell would have
to undergo several hundred synchronous mutations and a significant evolution
of its cell membranes to resist the effects of byotrol and we are very clear
this is highly unlikely. This is why Byotrol is so exciting, because it
takes well known and well understood chemicals and without altering them
chemically makes a huge change in their performance in use.

In closing I trust that you find this useful, and please forgive my
scientific upbringing that will not allow me to use phrases such as no risk
whatsoever and perfectly safe, but be reassured we were very alert to this
issue and believe that Byorol's shareholders need have no worries over this
aspect of our technology

Yours sincerely
Stephen Falder

Dictated to
Alison Patterson in Stephen Falder's absence
Office Manager
BYOTROL

Useful link about Byotrol products, posted on ADVFN.

http://www.hansonco.net/byotrol.html

Just been reading in the press, that a secret Government probe, has been looking into the impact of scrapping weekly rubbish collections.It's found that if it's made fortnightly (As it is in a third of councils in England & Wales).The risk of M.R.S.A. is far greater.I wonder if anyone at Byotrol is aware of this.
It could have an impact on the share price, if the company decided to supply councils with their products, to binmen & other employees.

Source:Daily Express 17th October

You're telling me that the UK is now sinking in rubbish? Don't ask me why I no longer live there . . . .

More good news that several multi-national companies have approached Byotrol about using there products.
Does anyone know who?

Please forgive me if this is a stupid question, as I'm just a private investor who bought into Byotrol on it's M.R.S.A. trials.

With the recent outbreak of bird flu wouldn't the use of byotrol technology be beneficial in helping to prevent bird flu outbreaks?

Bird flu is due to H5N1 that has mutated into a variety of strains with differing pathogenic profiles, some pathogenic to one species but not others, some pathogenic to multiple species. Each specific known genetic variation is traceable to a virus isolate of a specific case of infection. Through antigenic drift, H5N1 has mutated into dozens of highly pathogenic varieties divided into genetic clades which are known from specific isolates, but all currently belonging to genotype Z of avian influenza virus H5N1, now the dominant genotype.

So it is not so easy to eliminate bird flu. By the time Byotrol produces a treatment, it has mutated to another kind.

A favourable article in late June National Press has transformed this stock . . . bvut I still have reservations - it might be possible to pay "too much" before the profits start rolling.

AND - as far as I'm aware MRSA is still with us.

(Unless you are using "Dettol", that is)

They need to diversify and look into killing not just MRSA, but also Clostridium difficile.

Byotrol plc is engaged in the development, patenting and sale of products based on microbial technology. The Company operates in three segments: product sales, license fees and royalties. Its products can be used for a range of healthcare situations, from routine environmental cleaning to sanitization and disinfection. The Byotrol Assure range includes ready-for-use sprays and wipes for hard surfaces and instruments, liquids for hand cleaning and as dilute-to-use formulations for larger volume applications. The Agrisphere product range offers microbial control and helps protect against a number of hygiene issues that farmers face, including digital dermatitis, foot rot and salmonella. The Nanosphere product range offers microbial control against microbes, including Listeria, Legionella, E.coli, Salmonella, S aureus and campylo bacter. In February 2010, the Company acquired the business and certain assets of Byofresh Limited.

Every little helps...

Byotrol has been awarded a research grant by North West Development Agency. The NWDA grant, totalling 443,824, is to be paid over three years to develop, in particular, the range of applications in the consumer products division.

Byotrol secure agreement with Kimberley-Clark
StockMarketWire.com
Byotrol Consumer Products (BCP), Byotrol's 50% owned consumer products subsidiary, and Kimberly-Clark have agreed to enter into a full licensing agreement.

Details of the agreement are not being disclosed at this time and follows the successful completion of the initial joint development agreement with a Fortune 150 partner which Byotrol announced in January.

The new, seven-year contract is global in scope, with some exceptions including certain EU markets, and provides Kimberly-Clark exclusive intellectual property rights.

Kimberly-Clark's global brands sell in more than 175 countries. With names such as Kleenex, Scott, Huggies, Pull-Ups, Kotex and Depend, it holds the No. 1 or No. 2 share position in more than 80 countries.

Commenting on the commercial agreement, Ralph Kugler, Chairman at Byotrol, said: "This is a landmark agreement for Byotrol. It realises a central tenet of our strategy by partnering with a global consumer-focussed company.

"We are delighted to have worked so closely with a company as respected as Kimberly-Clark in arriving at this significant result, and we appreciate the commitment to Byotrol that Kimberly-Clark has shown from the earliest stage. The agreement also reflects the outstanding effort made by our partners at BCP."

Hello dreamcatcher: A good Manchester company (I should know, that’s where I'm from........Now in Kent)..........This company has struggled to get of the launch pad; I got severely burnt a couple of years back......I paid 21p, sold at 9p......oooch.
Hygiene antibacterial products. In my opinion, I feel they need large Hospital/laboratory type contracts.

I thought they would have moved when they got a contract with Rentokil........Shot up from 8p to 16p in a day........Then retreated to 6p and less.

Not sure when to re-enter.........Need to see momentum around the 8p mark, then I'm in!

Starting to climb G18 . Sorry to hear that. Lets hope you make your money back and more. :-)) Not invested here

Audio interview with Gary Millar, Chief Executive of Byotrol
Gary Millar, Chief Executive of Byotrol, discusses the interim results for the international hygiene business. The past six months saw many operational highlights including the licensing agreement with Kimberly Clark.

Click the link below to listen:

http://www.brrmedia.co.uk/event/106818/gary-millar-chief-executive

Gary Millar, Chief Executive of Byotrol, provides a commercial and trading update focusing on the significant announcement that Byotrol is to be adopted across Marks and Spencer stores. Byotrol sanitisers will now be used as thier in-store surface hygiene solution.
Click the link to listen to the interview;
http://www.brrmedia.co.uk/event/109637/gary-millar-chief-executive